Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tyra Biosciences
Biotech
Tyra rolls toward pivotal cancer study even as stock deflates
Tyra reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year.
Nick Paul Taylor
Sep 9, 2026 9:30am
Tyra banks $173M to bring cancer resistance programs into clinic
Sep 15, 2021 10:20am
Tyra Biosciences wants to bank $100M for an IPO
Aug 23, 2021 7:05am
Tyra banks $106M, adds to C-suite as it aims for clinic in 2022
Mar 31, 2021 11:00am